We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Plasma Biomarkers Predict Severity of Malaria Infection

By LabMedica International staff writers
Posted on 29 Sep 2010
Two biomarkers have been found suitable to assess the severity of malaria in travelers returning with the disease. More...


The diagnostic accuracy of plasma soluble Triggering Receptor Expressed on Myeloid cells 1 (TREM-1), neopterin and procalcitonin levels as biomarkers for severe Plasmodium falciparum disease was evaluated. Neopterin belongs to the chemical group known as pteridines and procalcitonin is a peptide precursor of the hormone calcitonin. Both substances are involved in the systemic proinflammatory response of the host to invading pathogens.

In a study carried at the Erasmus Medical Center (Rotterdam, the Netherlands), levels of the biomarkers for severe P. falciparum disease was evaluated in 104 travelers with imported malaria. Twenty-six patients had non-P. falciparum malaria, 64 patients were with uncomplicated P. falciparum malaria and 14 patients had severe P. falciparum malaria). The diagnostic performance of TREM-1, procalcitonin and neopterin for malaria disease severity was compared with that of plasma lactate, which is routinely measured in returning travelers who are ill.

Malaria was diagnosed by Quantitative Buffy Coat analysis, by a rapid diagnostic antigen test for malaria and by conventional microscopy of stained thick and thin blood smears. TREM-1 and neopterin levels were determined in serum samples using commercially available enzyme-linked immunoassay (ELISA) tests. Procalcitonin levels in serum samples were determined using a commercially available enzyme immunoassay test. Normal serum values are <100 pg/mL for TREM-1, <3 ng/mL for neopterin and < 0.1 ng/mL for procalcitonin.

Patients with severe P. falciparum malaria had significantly higher neopterin and procalcitonin levels on admission when compared to patients with uncomplicated P. falciparum malaria or non-P. falciparum malaria. No significant differences in TREM-1 levels were detected between the different patient groups. At a cut-off point of 10.0 ng/mL, neopterin had a positive and negative predictive value of 0.38 and 0.98, whereas procalcitonin, at a cut-off point of 0.9 ng/mL, had a positive and negative predictive value of 0.30 and 1.00. The study was published online in September 14, 2010, in the Malaria Journal.

Although the diagnostic value of neopterin and procalcitonin is limited, the high negative predictive value of both neopterin and procalcitonin may be helpful for a rapid exclusion of severe malaria disease on admission. This may be a valuable tool for physicians only occasionally dealing with returned travelers from malaria-endemic regions and who need to decide on subsequent oral antimalarial treatment or timely referral to a specialized center for high-level monitoring and intensified parenteral treatment.

Related Links:
Erasmus Medical Center



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.